# US 2015/0105337 A1 · Enterobactin conjugates and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105337 A1
- Document ID: US20150105337A1
- Status: Published application
- Kind: A1
- Application number: 14/516,440
- Filed: 2014-10-16
- Published: 2015-04-16
- Earliest claimed: 2013-10-16
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Elizabeth Marie Nolan; Tengfei Zheng; Phoom Chairatana
- Web page: https://patentgrep.com/patent/US20150105337A1

## CPC

- C12Q 1/06: Quantitative determination
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- C07H 7/04: Carbocyclic radicals
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.

## Claims

### Claim 1

A compound of Formula (I):
or a salt thereof, wherein:
each instance of L is independently a bond or a divalent linker;
one instance of X is an antibiotic, a fluorophore, or a biotin moiety of the formula:
all other instances of X are independently selected from the group consisting of hydrogen, an antibiotic, a fluorophore, and a biotin moiety of the formula:
one instance of n is 1, 2, or 3; and
the other two instances of n are independently 0, 1, 2, or 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is not of the formula:
or a salt, hydrate, solvate, polymorph, co-crystal, tautomer, or isotopically labeled derivative thereof, wherein -Pep is a monovalent radical of a peptide of the sequence: GETDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQGLIDHGPVNVPIP VLIGPSWNGSSSGYNSATSSSGSGS (SEQ ID NO: 11), wherein the carbonyl moiety of the C-terminus of Pep- is attached to the oxygen atom at C6 of the glucose moiety.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is of the formula:
or a salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is of the formula:
or a salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is of the formula:
or a salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is of the formula:
or a salt thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is of the formula:
or a salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is of the formula:
or a salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein at least one instance of L is hydrolytically stable under physiological conditions.

### Claim 10 (depends on 1)

The compound of claim 1, wherein at least one instance of L is hydrolytically unstable under physiological conditions.

### Claim 11 (depends on 1)

The compound of claim 1, wherein:
each instance of L is independently a bond or a substituted or unsubstituted C1-100 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with —O—, —S—, —NRL—, —S(═O)—, —S(═O)2—, or substituted or unsubstituted heteroarylene; and
each instance of RL is independently hydrogen, substituted or unsubstituted C1-6 alkyl, or a nitrogen protecting group.

### Claim 12 (depends on 11)

The compound of claim 11, wherein one carbon unit of at least one instance of L is replaced with unsubstituted heteroarylene of the formula

### Claim 13 (depends on 11)

The compound of claim 11, wherein one carbon unit of each instance of L is replaced with unsubstituted heteroarylene of the formula:

### Claim 14 (depends on 11)

The compound of claim 11, wherein at least one instance of L is of the formula:
wherein:
L and L4 are independently —NRLC(═O)— or —C(═O)NRL—;
L2 and L3 are independently unsubstituted C1-50 alkylene or C1-50 alkylene substituted with at least one halogen, optionally wherein one to six carbon units of the C1-50 alkylene are replaced with —O—;
L5 is a bond, unsubstituted C1-6 alkylene, or C1-6 alkylene substituted with at least one halogen, optionally wherein one or two carbon units of the C1-6 alkylene are replaced with —O—; and
L6 is unsubstituted C2-90 alkylene, or C2-90 alkylene substituted with at least one halogen, optionally wherein one to eight carbon units of the C2-90 alkylene are replaced with —O—.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the molecular weight of at least one instance of X is less than about 300 Da.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the molecular weight of at least one instance of X is less than about 1.4 kDa.

### Claim 17 (depends on 1)

The compound of claim 1, wherein at least one instance of -L-X is -(divalent carbohydrate radical)-H.

### Claim 18 (depends on 17)

The compound of claim 17, wherein at least one instance of -L-X is -(divalent glucose radical)-H.

### Claim 19 (depends on 17)

The compound of claim 17, wherein at least one instance of -L-X is of the formula:

### Claim 20 (depends on 1)

The compound of claim 1, wherein at least one instance of X is an antibiotic.

### Claim 21 (depends on 20)

The compound of claim 20, wherein the antibiotic is effective against a Gram-negative bacterium.

### Claim 22 (depends on 20)

The compound of claim 20, wherein the antibiotic is a β-lactam antibiotic.

### Claim 23 (depends on 1)

The compound of claim 1, wherein at least one instance of X is a fluorophore.

### Claim 24 (depends on 1)

The compound of claim 1, wherein at least one instance of X is of the formula:

### Claim 25 (depends on 1)

A complex comprising a compound of claim 1, or a salt thereof, and Fe(III).

### Claim 26 (depends on 1)

A complex comprising a compound of claim 1, or a salt thereof, and Ga(III).

### Claim 27 (depends on 23)

A complex comprising a compound of claim 23, or a salt thereof, and Fe(III).

### Claim 28 (depends on 23)

A complex comprising a compound of claim 23, or a salt thereof, and Ga(III).

### Claim 29 (depends on 20)

A pharmaceutical composition comprising a compound of claim 20, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29 further comprising an iron chelator.

### Claim 31 (depends on 29)

The pharmaceutical composition of claim 29 further comprising Fe(III).

### Claim 32 (depends on 29)

The pharmaceutical composition of claim 29 further comprising Ga(III).

### Claim 33 (depends on 23)

A composition comprising a compound of claim 23, or a salt thereof, and optionally an excipient.

### Claim 34 (depends on 33)

The composition of claim 33 further comprising an iron chelator.

### Claim 35 (depends on 33)

The composition of claim 33 further comprising Fe(III).

### Claim 36 (depends on 33)

The composition of claim 33 further comprising Ga(III).

### Claim 37 (depends on 20)

A method of treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 20, or a pharmaceutical acceptable salt thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein the bacterial infection is cause by a Gram-negative bacterium.

### Claim 39 (depends on 20)

A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 20, or a pharmaceutical acceptable salt thereof.

### Claim 40 (depends on 20)

A method of treating inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 20, or a pharmaceutical acceptable salt thereof.

### Claim 41 (depends on 37)

The method of claim 37, wherein the subject is a mammal.

### Claim 42 (depends on 37)

The method of claim 37, wherein the subject is a human.

### Claim 43 (depends on 1)

A method of delivering an antibiotic, a fluorophore, or a biotin moiety of the formula:
to a bacterium, the method comprising contacting the bacterium with a compound of claim 1, or a salt thereof.

### Claim 44 (depends on 1)

A method of determining the concentration of a bacterium in a biological sample, the method comprising contacting the biological sample with an effective amount of a compound of claim 1, or a salt thereof.

### Claim 45 (depends on 43)

The method of claim 43, wherein the bacterium is a Gram-negative bacterium.

### Claim 46 (depends on 21)

The compound of claim 21, wherein the Gram-negative bacterium is an Escherichia species, a Pseudomonas species, a Klebsiella species, a Salmonella species, or an Acinetobacter species.

### Claim 47 (depends on 46)

The compound of claim 46, wherein the Gram-negative bacterium is an Escherichia coli strain or a Pseudomonas aeruginosa strain.

### Claim 48 (depends on 1)

A kit comprising:
a compound of claim 1, or a salt thereof; and
instructions for using the kit.

### Claim 49

A compound of Formula (A1) or (A2):
or a salt thereof, wherein:
each instance of LA is independently a bond or substituted or unsubstituted C1-17 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with —O—, —S—, —NRLA—, —S(═O)—, or —S(═O)2—; and
each instance of RLA is independently hydrogen, unsubstituted C1-6 alkyl, C1-6 alkyl substituted with at least one halogen, or a nitrogen protecting group; and
one instance of m is 1, 2, or 3; and
two instances of m are independently 0, 1, 2, or 3.

### Claim 50 (depends on 12)

A method of preparing a compound of claim 12, or a salt thereof, the method comprising:
contacting a compound of Formula (A1), or a salt thereof, with a compound of Formula (B1), or a salt thereof, or contacting a compound of Formula (A2), or a salt thereof, with a compound of Formula (B2), or a salt thereof:
X-LB-C≡CH (B1)
X-LBN3 (B2),
wherein:
each instance of LB is independently a bond or substituted or unsubstituted C1-17 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with —O—, —S—, —NRLB—, —S(═O)—, or —S(═O)2—; and
each instance of RLB is independently hydrogen, unsubstituted C1-6 alkyl, C1-6 alkyl substituted with at least one halogen, or a nitrogen protecting group.
